



# **Histamine & antihistamine drugs**

**Dr. Nashwa Aborayah**

**Associate professor of clinical and experimental  
pharmacology**

**Mu'tah University- Faculty of Medicine**

**Respiratory module**

**JORDAN 2024/2025**



# Objectives

- What is histamine?
- Histamine releasers
- Clinical symptoms associated with histamine release
- Histamine receptors and its pharmacological actions
- Drugs antagonizing histamine actions
- What are meant by antihistamines?
- Clinical uses of antihistaminics
- Adverse effects of antihistaminics
- Classes of antihistaminics

# Histamine


• **Histamine is an endogenous substance synthesized, stored and released in:**

(a) mast cells, which are abundant in the skin, GI, and the respiratory tract


(b) basophils in the blood

(c) some neurons in the CNS and peripheral NS

## Major Histamine-producing Cells



## Minor Histamine-producing Cells



# Histamine Release

- **Immunologic Release (Cell destruction) (IgE- mediated):**
  - mast cell & basophils are degranulated when exposed to the appropriate antigen (bacterial toxins, venom, cold, food, some drugs)
- **Chemical Release (non- immunological) :** by drugs: like morphine, vancomycin & curare, X-ray contrast media

# Clinical Symptoms Associated With Histamine Release

- mild/cutaneous
  - mild to moderate
  - severe/anaphylactic
- erythema, urticaria, and/or itching
  - skin reactions, tachycardia, dysrhythmias, moderate hypotension, mild respiratory distress
  - severe hypotension, ventricular fibrillations, cardiac arrest, bronchospasm, respiratory arrest





# Histamine Receptors: Distribution and Function

• Histamine has four histamine H<sub>1</sub>, H<sub>2</sub>, H<sub>3</sub>, & H<sub>4</sub> G-protein coupled receptors

• **H<sub>1</sub>** – Smooth muscle fibers, endothelium, CNS, nerve endings:

• Bronchoconstriction, vasodilation (relaxation of precapillary sphincters), motion sick, memory and wakefulness, increasing secretions of exocrine glands, severe itching

• **H<sub>2</sub>** – gastric parietal cell, heart, mast cell:

• Regulate gastric acid secretion, positive inotropic, inhibition of IgE-dependent degranulation (negative feedback).

• **H<sub>3</sub>** - CNS cells, and some in peripheral NS. Presynaptic:

• feedback inhibition of histamine synthesis and release. They also control release of DA, GABA, ACh, 5-HT & NE

• **H<sub>4</sub>** - Highly expressed in immune cells: immunity modulation



# Molecular biology of H<sub>1</sub> receptors

□ **Vasodilatation** is via endothelial H<sub>1</sub> receptors

• H<sub>1</sub> stimulation → Increased intracellular Ca<sup>2+</sup> → Activation of PLA<sub>2</sub> → PGI<sub>2</sub> & NO production → Diffusion to smooth muscles → vasodilatation

□ **Contraction of bronchi, intestine and other smooth muscle fibers** occur via stimulation of *PLC-coupled H<sub>1</sub> receptors* followed by increased IP<sub>3</sub> & DAG: increasing intracellular Ca<sup>2+</sup>


# Triple Response of Willis

**Subdermal histamine injection causes:**

**1.Red spot** (few mm) in seconds: direct vasodilation effect , H1 receptor mediated

**2.Flare** (1cm beyond site): axonal reflexes, indirect vasodilation, and itching, H1 receptor mediated

**3.Wheal** (1-2 min) same area as original spot, edema due to increased capillary permeability, H1 receptor mediated



# Drugs antagonizing histamine actions

- 1- Physiologic antagonism?
- 2- Mast Cell Stabilizers (**Cromolyn Na, ketotifen**)
- 3- Receptor antagonism:
  - H1 Receptor Antagonists (**1<sup>st</sup> and 2<sup>nd</sup> generation**)
  - H2 Receptor Antagonists (**Ranitidine, Cimetidine**)
  - H3 Receptor Agonist and Antagonists (potential new drugs being developed)
- 4- Immunotherapy ( desensitization)

# What is an antihistaminic?

- A drug that reduces or eliminates the effects mediated by histamine
- The term antihistamine **only refers to H<sub>1</sub> receptor antagonists**
- Antihistamines compete with histamine for binding sites at the receptors
- Antihistamine cannot remove the histamine if it is already bound
- More effective in preventing the actions of histamine rather than reversing them
- Should be given early in treatment, before all the histamine binds to the receptors

# Clinical Uses of Antihistamines


- **1- Allergy:** (both 1<sup>st</sup> and 2<sup>nd</sup> generations)
  - Allergic rhinitis (common cold)
  - Allergic conjunctivitis (pink eye)
  - Anaphylactic reactions (severe allergies)
  - **Allergic dermatological conditions:**
    - A- Urticaria (hives)
    - B- Angioedema (swelling of the skin)
    - C- Pruritus (atopic dermatitis, insect bites)
- **2- Motion sickness, vertigo** (first generation H<sub>1</sub>-antihistamines)
- **3- Sedative/sleep aid** (1<sup>st</sup> generation)
- **4- Carcinoid syndrome:** cyproheptadine



# Adverse effects

- Associated with the **first generation H<sub>1</sub>-antihistamines** and due to their lack of selectivity for the H<sub>1</sub>:
- **1- Sedation:** lipophilic: pass BBB
- **EXCITATION** in children under 6 years age (atropine-like)
- **2- Atropine-like action:**
- Blurred vision, dry mouth, urine retention (esp. old age), glaucoma (old age)
- **3- Alpha blocking action:** orthostatic hypotension and tachycardia
- **4- Serotonin blocking action** (cyproheptadine): weight gain, dry mouth, drowsiness
- 5- Newer second generation H<sub>1</sub>-antihistamines are more selective for the peripheral histamine receptors and have less side effects, BUT
- **Serious types of arrhythmias(fatal):** (Torsade de pointes) prolongation of QT-interval: astemizole





## TORSADES DE POINTES

The diagram illustrates the mechanism of torsades de pointes. It shows a normal QRS complex (blue) followed by a prolonged QT interval (red), which leads to the development of torsades de pointes (red). The text "PROLONGED QT INTERVAL" is shown with a double-headed arrow indicating the duration of the prolonged QT interval. The text "TWISTING of the POINTS" is shown with a curved arrow indicating the twisting nature of the QRS complexes. A green banner at the bottom contains the text "LEARN MORE on OSMOSIS.org!".

PROLONGED QT INTERVAL

"TWISTING of the POINTS"


LEARN MORE on [OSMOSIS.org!](https://www.osmosis.org)

# First generation H<sub>1</sub> receptor antagonist

- **Mepyramine**
- **Diphenhydramine:**
  - Oldest
  - Available over the counter
  - Because it induces sedation, it's used in nonprescription sleep aids
- **Dimenhydrinate:** Anti-emetic
- **Cyclizine:** motion sickness
- **Cetirizine (Zyrtec):** allergies and is safe to use in children as young as 2
- **Kitotifen**
- **Cyproheptadine**

- **Levocetirizine:**

- This drug is the active enantiomer of cetirizine
- Also it is not metabolized and is likely to be safer than other drugs due to a lack of possible drug interactions.
- It does not cross the BBB and does not cause significant drowsiness



## **Second generation H<sub>1</sub>-receptor antagonists**

- These are the newer drugs and they are much more selective for the peripheral H<sub>1</sub>-receptors involved in allergies than to the H<sub>1</sub>-receptors in the CNS
- Therefore, these drugs provide the same relief with many fewer adverse side effects
- They are less lipophilic than the first generation drugs, therefore they do not cross the BBB as readily

## 1<sup>st</sup> generation

- **Short to intermediate action**
- **BBB cross**
- **Sedative action**
- **Produce anti muscurnic side effects**
- **Also block auonomic receptors**
- **Cheap**

## 2<sup>nd</sup> generations

- **Long acting**
- **Poor penetration**
- **No**
- **No**
- **No**
- **Relatively expensive**

# Second generation H<sub>1</sub>-receptor antagonists

- **Astemizole & Terfenadine**

- Have been taken off the market in most countries because of adverse interactions with erythromycin and ketoconazole (microsomal enzyme inhibitors) and effects on cardiac potassium channels

- **Loratidine, desloratidine**



## Third generation H<sub>1</sub>-receptor antagonists

- These drugs are derived from second generation antihistamines
- They are either the active enantiomer or metabolite of the second generation drug designed to have increased efficacy and fewer side effects
- **Fexofenadine** (the active metabolite of terfenadine), was approved in July 1996

# References

Cuss, F.M. "Beyond the histamine receptor: effect of antihistamine on mast cells." *Clinical and Experimental Allergy Review* 1999; 29: 54-59.

Devalia, J.L. and R.J. Davies. "Effect of antihistamines on epithelial cells." *Clinical and Experimental Allergy Review* 1999; 29: 64-68.

Mosges, R. and N. Krug. "Efficacy of antihistamines: from the precision of challenge models to the alchemy of clinical practice." *Clinical and Experimental Allergy Review* 2006; 6: 20-24.

Tillement, J.P. "Pharmacological profile of the new antihistamines." *Clinical and Experimental Allergy Review* 2005; 5:7-11

<http://www.netdoctor.co.uk/medicines/100002712.html>

<http://www.drugs.com>

<http://en.wikipedia.org/wiki/Antihistamines>

<http://www.drugbank.com>

*Thank you*